The Ministry of Health and Family Welfare has announced a major increase in funding for health research and a suite of new schemes to strengthen India’s research ecosystem.
Key Developments
- Budget allocation for the ICMR rises from ₹2,732.13 crore (2024‑25) to ₹3,125.50 crore (2025‑26) and reaches ₹4,000 crore in 2026‑27, a 21 % rise over the revised 2025‑26 estimate.
- ICMR revamps its grant architecture: ANVESHAN (≤₹2 cr), NISCHAYAK ANVESHAN (₹2‑8 cr), First‑in‑the‑World Challenge (≤₹8 cr) and Centres for Advanced Research (≤₹15 cr).
- Strategic programmes launched:
- Top‑Tier Global Leadership Funding Scheme for the top‑10 NIRF‑ranked medical colleges.
- ICMR‑NMC Joint Call for research on competency‑based medical education.
- MAHA‑MedTech mission (in partnership with Gates Foundation) to accelerate indigenous medical‑technology innovation.
- Launch of the Biopharma SHAKTI scheme to boost biopharma manufacturing and R&D.
Important Facts
The revised 2025‑26 estimate of ₹3,150 crore was superseded by a final allocation of ₹3,125.50 crore, and the 2026‑27 outlay of ₹4,000 crore marks a ≈21 % increase. New follow‑on grants will fund continuation of promising projects. Over 22 frontier‑technology projects (CAR‑T cell therapy, robotics‑based cancer therapy, etc.) are underway, and 97 indigenous medical devices have been developed, with cost reductions achieved for 11 of them.
Exam Relevance
Understanding the expanded health‑research budget helps answer GS‑3 questions on government spending, innovation policy, and the biotech sector. The grant categories illustrate how the state incentivises research at different maturity levels, a point for questions on public‑policy design. The involvement of NIRF ties higher‑education rankings to research funding, relevant for GS‑2 topics on education reforms. The Biopharma SHAKTI scheme aligns with India’s ‘Make in India’ and self‑reliance goals, a recurring theme in GS‑3 and GS‑4 ethics questions.
Way Forward
To maximise impact, the government should: (i) ensure transparent monitoring of grant utilisation; (ii) strengthen industry‑academia linkages for faster commercialization of medical devices; (iii) expand capacity‑building in clinical‑trial infrastructure; and (iv) promote regional research hubs to reduce concentration in metropolitan centres. Continuous evaluation will help India achieve global leadership in affordable medical technology and biopharma.